Warning: Trying to access array offset on value of type bool in /www/wwwroot/www.medtourcn.com/wp-content/themes/medical-directory/framework/theme/medicaldirectory-image.php on line 78

Warning: Trying to access array offset on value of type bool in /www/wwwroot/www.medtourcn.com/wp-content/themes/medical-directory/framework/theme/medicaldirectory-image.php on line 79

3 months ago patient story

Multiple myeloma

After a period of treatment, the Singaporean patient Teresa achieved remarkable results with CAR-T therapy at Jiahui International Hospital in Shanghai. Her condition reached complete remission (CR), and to celebrate this great news, the hospital held a brief yet heartwarming celebration for her.

In the celebratory photos, Teresa, along with Dr. Vicky Lee and her team of doctors and nurses, are all smiles, radiating the joy of victory. The photos not only captured this happiness but also served as a testament to the hard work and professionalism of the medical staff. Every member of Dr. Vicky Lee’s team is a true hero, using their expertise and selfless dedication to help Teresa overcome her illness.

Teresa, filled with emotion, said: “Although the treatment process was tough, I felt immense warmth and support from the doctors and nurses at Jiahui Hospital. Their professionalism and care gave me confidence, which ultimately led to such a successful outcome.”

On the day of her discharge, the medical staff extended their heartfelt blessings to Teresa. The nurses kindly reminded her of the precautions she needed to take after leaving the hospital, ensuring she could maintain good health during her recovery at home. Teresa expressed her gratitude to each member of the medical team, thanking them for the care and support they provided when she needed it most.

Standing at the hospital entrance, Teresa looked back on her treatment journey, filled with gratitude and hope. She knew that it was because of the selfless dedication and outstanding professionalism of these medical professionals that she could embrace health once again and look forward to a new chapter in life.

Teresa’s recovery story is not only a personal victory but also the result of the collective efforts of the entire medical staff at Jiahui Hospital. She is deeply grateful for their hard work and believes that many more patients will find new hope for recovery here in the future.

We will continue to follow the patient’s post-treatment progress and provide updates.

#CART #CARTTherapy #Hopeforpatients #FUCASO #Equecel #MultipleMyeloma #jihuiHospital #Shanghai #ChineseCart #MedicalInnovation #MedicalBreakthrough #CancerTreatment #FullyHumanCART #cancerfight #cancersurvivor #Jiahuihospital

3 months ago patient story

庆祝出院：新生的喜悦 /希望之路 /与癌症抗争 /希望 /CART/多发性骨髓瘤

###庆祝出院：新生的喜悦

经过一段时间的治疗，新加坡患者Teresa在上海嘉会国际医院的CAR-T治疗取得了令人振奋的成果。她的病情完全达到了完全缓解（CR），在这一喜讯的见证下，医院为她举行了一场简短而温馨的庆祝活动。

在庆祝合影中，Teresa与Dr. Vicky Lee及其团队的医生护士们笑容满面，洋溢着胜利的喜悦。照片不仅记录了这份喜悦，也见证了医护人员的辛勤付出和专业精神。Dr. Vicky Lee和团队的每一位成员都是真正的英雄，他们用专业知识和无私奉献帮助Teresa战胜了病魔。

Teresa感慨万千，她说：“这段时间的治疗过程虽然艰辛，但在嘉会医院医生和护士们的悉心照料下，我感受到了无比的温暖与支持。他们的专业和关怀让我充满了信心，最终取得了这样的好结果。”

出院那天，医护人员为Teresa送上了最真挚的祝福。护士们亲切地叮嘱她出院后的注意事项，确保她在回家后的康复过程中能够继续保持良好的健康状态。Teresa感激地与每一位医护人员道别，感谢他们在她最需要的时候给予的关爱和支持。

站在医院门口，Teresa回望这段治疗旅程，心中充满了感激和希望。她知道，正是因为有了这些无私奉献、专业卓越的医护人员，她才能重新拥抱健康，迎接新的生活。

Teresa的康复故事不仅是她个人的胜利，更是嘉会医院全体医护人员共同努力的成果。她深深感谢他们的辛勤付出，并相信未来将会有更多的患者在这里获得新生的希望。

我们将持续关注患者的治疗后续，并跟进报道。

4 months ago Myeloma

Overcoming Challenges and Embracing New Life! – Breakthrough Progress of Eque-cel in the Treatment of Refractory Multiple Myeloma

### Overcoming Challenges and Embracing New Life! – Breakthrough Progress of Eque-cel in the Treatment of Refractory Multiple Myeloma

Multiple Myeloma

In the treatment of multiple myeloma (MM), how do we find new breakthroughs for patients who have not achieved complete remission (CR) after multiple rounds of chemotherapy? Research by Chinese medical professors has provided an exciting answer: Eque-cel (BCMA CAR-T therapy).

Patient Background:

This 58-year-old female patient was initially admitted to the hospital due to numbness and pain in both lower limbs and was eventually diagnosed with multiple myeloma. Despite receiving various treatment regimens, including VRD and SVPD, the results were unsatisfactory, and complete remission was not achieved. Faced with refractory characteristics, the doctors decided to try a more innovative treatment plan—CAR-T cell therapy.

Treatment Process:

In September 2023, the patient began peripheral blood mononuclear cell collection, followed by bridging therapy, and in November 2023, she received the Eque-cel infusion. Remarkably, just one month later, the patient achieved hematologic complete remission (CR) with minimal residual disease (MRD) negativity. After six months of follow-up, the patient maintained this excellent therapeutic effect.

Professor’s Insights:

Chinese medical professors pointed out that the advent of Eque-cel has brought new hope to refractory MM patients. The drug demonstrated significant efficacy in the FUMANBA-1 study: the overall response rate was as high as 98.9%, with 82.4% achieving complete remission, and 97.8% of patients achieving MRD negativity. The 12-month sustained MRD negativity rate reached 81.7%, and the PFS rate was 85.5%.

This outstanding result proves the significant advantage of Eque-cel in improving the depth of remission for MM patients, bringing hope for long-term survival to many refractory patients.

Future Outlook:

As the application and research of Eque-cel continue, we look forward to it providing better treatment options and survival opportunities for more MM patients. This new treatment plan is bringing a ray of hope to this stubborn disease and providing valuable experience for clinical experts worldwide.

Stay Tuned:

We will continue to follow the latest developments and research progress of Eque-cel, looking forward to its greater role globally, bringing hope and blessings to more patients.

To assess whether the condition is suitable for CAR-T or clinic therapy, you can submit Advanced Medicine in China for preliminary evaluation!

WhatsApp:+8613717959070

Email: doctor.huang@globecancer.com

#MultipleMyeloma #CARTTherapy #MedicalBreakthrough #EqueCel #CancerTreatment #MedicalResearch #Hematology #PatientCare #OncologyInnovation #HopeForPatients #BCMA #CART #MM #RRMM

4 months ago CAR-T

“Thank you,” Teresa said to the doctors and nurses with a smile, “Your professionalism and care make me feel incredibly reassured. I believe that with you by my side, I will conquer this illness.”

### Gratitude to the Doctors and Nurses at Jiahui International Hospital in Shanghai:

After undergoing the processes of apheresis and reinfusion, Teresa feels immense gratitude towards the doctors and nurses at Jiahui International Hospital in Shanghai. She has deeply experienced the professionalism and care of the medical staff.

Under the guidance of Dr. Vicky Lee and her team, the entire collection and infusion process became smooth and reassuring. Every doctor and nurse patiently explained each step, effectively prevented and assessed the risks that might occur after reinfusion, and constantly monitored her physical condition and emotional changes, providing meticulous care and comfort. They also offered tremendous psychological support. The warm words and determined eyes of the doctors and nurses gave Teresa strength during moments of uncertainty.

It is precisely the professionalism and compassion of these healthcare workers that filled Teresa with confidence and hope on her journey to fight the illness. She sincerely thanks all the medical staff at Jiahui Hospital. Their dedication and care have shown her the hope of recovery.

We will continue to follow up on the patient’s treatment progress and provide updates.

#CART #CARTTherapy #Hopeforpatients #FUCASO #Equecel #MultipleMyeloma #jihuiHospital #Shanghai #ChineseCart #MedicalInnovation #MedicalBreakthrough #CancerTreatment #FullyHumanCART #cancerfight #cancersurvivor #Jiahuihospital

4 months ago CAR-T

“谢谢你们，”Teresa微笑着对医生和护士们说道，“你们的专业和关爱让我感到无比安心。我相信，有了你们，我会战胜这场病魔。”

感谢上海嘉会国际医院的医生护士：

在经历了单采，回输等过程后，Teresa对上海嘉会国际医院的医生和护士们心怀感激。她深深体会到了医护人员的专业和关怀。

在Dr. Vicky Lee及其团队的指导下，整个采集输注过程变得顺利和安心。每一位医生和护士都耐心解释每一个步骤，甚至对回输后会出现的风险都做了有效预防和评估，时刻关注她的身体状况和情绪变化，给予她无微不至的照顾和安慰。并且在心理上给予了莫大的支持。医生和护士的温暖话语和坚定目光，让Teresa在不安时找到了力量。

正是这些医护人员的专业和爱心，让Teresa在对抗病魔的路上充满了信心和希望。她由衷地感谢嘉会医院的全体医护人员，是他们的付出和关怀，让她看到了康复的希望。

我们将持续关注患者的治疗后续，并跟进报道。

4 months ago Lymphoma

2024 ASCO | Relma-cel Achieves a 4-Year OS Rate of 66.7% in Treating R/R LBCL, Making Lymphoma Cure Possible

Lymphoma

Over the past few decades, there have been significant advancements in the treatment of hematologic malignancies, particularly with CAR-T cell therapy. Recently, Relma-cel (relmacabtagene autoleucel) showcased promising new data at the 2024 American Society of Clinical Oncology (ASCO) Annual Meeting, highlighting its remarkable efficacy in treating relapsed/refractory large B-cell lymphoma (R/R LBCL).

### Breakthrough in CAR-T Therapy

Relma-cel is a CD19-targeted CAR-T cell therapy that reprograms a patient’s own T cells to recognize and attack cancer cells. Studies have shown that Relma-cel achieves a 4-year overall survival (OS) rate of 66.7% in patients with R/R LBCL, with the rate soaring to 82.5% for those who achieve complete remission (CR). These results indicate that Relma-cel not only significantly extends survival but also increases the cure rate for these patients.

### The Power of Long-Term Follow-Up Data

The RELIANCE study, one of the largest CAR-T cell therapy studies in China, aims to evaluate the efficacy and safety of Relma-cel in R/R LBCL patients. The latest 4-year follow-up data reveals that 25 patients remain alive, and the median overall survival (OS) has not yet been reached. This milestone offers immense hope for patients and physicians, underscoring the long-term survival benefits of this therapy.

### Balancing Safety and Efficacy

Relma-cel also excels in safety. The incidence rates of ≥3 grade cytokine release syndrome (CRS) and neurotoxicity (NT) are 5.1% and 3.4%, respectively. Compared to other CD19 CAR-T cell therapies, Relma-cel effectively reduces side effects while significantly enhancing efficacy. This success is largely attributed to its unique CAR structure design, which includes a 4-1BB costimulatory domain, a CD28 transmembrane domain, and an optimized hinge region. These features enable Relma-cel to survive longer in the body and enhance its tumor-killing power.

### Future Prospects

As Relma-cel continues to expand its reach, more R/R LBCL patients are expected to benefit from this advanced treatment. Currently, Relma-cel is exploring its potential use in second-line treatment for LBCL and frontline therapy for high-risk LBCL patients. Additionally, it has shown excellent clinical value in treating relapsed/refractory follicular lymphoma (R/R FL) and mantle cell lymphoma (R/R MCL).

Relma-cel’s success not only brings new hope to lymphoma patients but also signifies a new era in the treatment of hematologic malignancies. We look forward to more research findings on Relma-cel, which will bring hope and possibilities for curing lymphoma to patients worldwide.

With Relma-cel, curing lymphoma is no longer an unattainable dream. Let’s anticipate more breakthroughs in this field, bringing new light to the lives of every patient.

🎉🎉To assess whether the condition is suitable for CAR-T or clinic therapy, you can submit Advanced Medicine in China for preliminary evaluation!

WhatsApp: +8613717959070

Email: doctor.huang@globecancer.com

#LymphomaTreatment #CAR_TTherapy #CancerResearch #RelmaCel #HopeForPatients #MedicalAdvancements #ASCO2024 #InnovativeTherapies #Survivorship #CureLymphoma

7 months ago Myeloma

The world’s first #CART therapy approved for second-line treatment of multiple myeloma is claimed by a Chinese pharmaceutical company

Mutiple myeloma

#Legend Biotech

How to advance #CARTcell therapy to frontline treatment is the goal every CAR-T company strives for. On April 5, 2024, local time, Chinese pharmaceutical company Legend Biotech (LEGN.NS) shared exciting news as the U.S. Food and Drug Administration (#FDA) officially approved #ciltacabtageneautoleucel for treating relapsed or refractory multiple myeloma patients. This significant decision brings new hope to patients who have undergone first-line treatment and developed resistance to standard therapies.

#Ciltacabtagene autoleucel

Ciltacabtagene autoleucel becomes the world’s first CAR-T product approved for second-line treatment! This milestone event paves the way for Legend Biotech to enter the global CAR-T market. What’s even more inspiring is that just the day before, the FDA approved BMS’s CAR-T therapy Abecma for third-line treatment of multiple myeloma. The approval of ciltacabtagene autoleucel signifies the strong competitiveness and innovation capabilities of Chinese pharmaceutical companies in the CAR-T field.

Marketing

As early as February 28, 2022, ciltacabtagene autoleucel was first approved for marketing in the United States for the treatment of relapsed or refractory multiple myeloma in adults. As a pioneer of Chinese original CAR-T cell therapy, the successful market launch of this drug has won new glory for China’s biopharmaceutical industry. Currently, ciltacabtagene autoleucel is marketed in the United States, European Union, and Japan, and is also undergoing regulatory review in China, expected to be marketed domestically soon.

Personalized Immunotherapy

The CEO of Legend Biotech stated that the expanded indication of ciltacabtagene autoleucel is expected to change the treatment landscape of multiple myeloma, providing physicians and patients with a personalized immunotherapy option for early treatment. Multiple myeloma is an incurable and progressive hematologic malignancy, thus urgently requiring innovative treatment options, for which ciltacabtagene autoleucel is designed.

HOPE

The successful approval of ciltacabtagene autoleucel not only brings hope to patients but also outlines a new chapter for the future development of CAR-T therapy. In this hopeful moment, let’s look forward to CAR-T technology bringing health and happiness to more patients in the future!

To assess whether the condition is suitable for CAR-T or clinic therapy, you can submit Advanced Medicine in China for preliminary evaluation!

Email: doctor.huang@globecancer.com,

WhatsApp: 137 1795 9070

#LegendBiotech #CARTcell #MultipleMyelomaTreatment #Innovation #Hope

8 months ago patient story , Myeloma

🌈Treatment Across Continents: American Myeloma Patient Finds New Life in China!🌈

cancer fight

🌟Mr. C from California, USA

It’s yet another heartening piece of news as Mr. C from California, USA, undergoes cross-border treatment at Jiangsu Province People’s Hospital in China, successfully overcoming multiple myeloma and embracing a new lease on life! After meticulous treatment spanning one and a half months, Mr. C, accompanied by his loved ones, has made a successful recovery and been discharged from the hospital, becoming the first American patient to be successfully treated with CAR-T cell therapy for multiple myeloma in China.

🌞New treatment method

Mr. C, a 56-year-old American who is passionate about sports, discovered he had multiple myeloma after sustaining sports-related injuries. Despite enduring several unsuccessful treatment attempts, he refused to give up and began seeking treatment opportunities worldwide. However, the exorbitant cost of treating multiple myeloma in the USA deterred him. After comparing prices and data of CAR-T therapy for multiple myeloma between the USA and China, he ultimately decided to explore the new treatment method at Jiangsu Province People’s Hospital.

🌤Upon arriving in China,

Mr. C not only received meticulous care from medical staff but also had the opportunity to explore the scenic beauty of cities such as Nanjing, Suzhou, and Hangzhou, experiencing the unique cultural charm of China. During the CAR-T cell therapy treatment process, Mr. C underwent a life-threatening cytokine storm, but with the emergency intervention of the medical team, he successfully weathered the storm. Today, he has recovered and been discharged from the hospital, though slightly fatigued, he is still filled with hope and gratitude.

🔥Hope and Courage

Although Mr. C’s treatment has concluded, follow-up work will continue, with the medical team maintaining contact with his family doctor to closely monitor treatment effectiveness and subsequent conditions. As medical personnel, they sincerely hope that this treatment will provide Mr. C with more opportunities for survival.

☀️Mr. C also expressed his desire to revisit China, specifically Nanjing, to visit the experts and nurses who treated him, and of course, to continue savoring Chinese cuisine. This journey of treatment across continents not only granted Mr. C a new lease on life but also showcased the unity and dedication of medical personnel from both China and the USA. May this touching story inspire more people and bring forth more hope and courage!

⭐️CAR-T therapy

To assess whether the condition is suitable for CAR-T therapy, you can submit pathology reports, treatment history, and discharge summaries to the Medical Department of <Advanced Medicine in China> for preliminary evaluation!

You can send electronic copies or photos of genetic testing reports and diagnostic reports to:

💌: doctor.huang@globecancer.com
📞WhatsApp 137 1795 9070

✨The Medical Department will contact you as soon as receive the reports.

#CARTtherapy #LymphomaTreatment #CompleteRemission #MedicalAdvancements #CancerResearch #CARTProgress #HopeForPatients #SurvivingLymphoma #HealthcareInnovation #PatientStories #CancerCure #CARTSuccess #MedicalBreakthrough #ImprovingOutcomes #LymphomaAwareness #FightAgainstCancer #CARTJourney #MedicalMilestone #LongTermSurvival #BeatingCancer #lymphoma #cancerawareness

8 months ago patient story

🍀Чудесное путешествие через границы: триумф мистера Баранкова с китайской терапией CAR-T🍀

ЧудесноеПутешествие

🌿Познакомьтесь с мистером Баранковым,

68-летним пациентом из Санкт-Петербурга, Россия, который внезапно был диагностирован с множественной миеломой в 2018 году. После четырех лет международных консультаций он обнаружил, что Китай значительно продвинулся в области терапии CAR-T по сравнению с европейскими медицинскими учреждениями в Испании, Мюнхене, Гейдельберге и других странах. Результаты лечения в Китае ведущие в мире.

🌱После четырех лет лечения и рецидивов

После неудачной традиционной химиотерапии и двух автологичных трансплантаций гемопоэтических стволовых клеток, у него появилась возможность провести онлайн-консультацию с экспертами Международной больницы Цзяхуи в Шанхае. Во время виртуальной консультации господин Баранков был впечатлен опытом китайской медицинской команды и потенциалом лечения с помощью полностью человеческого препарата CAR-T FUCASO (Eque-cel). Учитывая лидирующее положение Китая в области терапии CAR-T, более конкурентоспособные затраты и относительно короткое время ожидания, господин Баранков принял решение отправиться в Китай для получения лечения.

☘️
#ЧудесноеПутешествие #ТерапияCART #ПересечениеГраниц #MiracleJourney #CARTTherapy #CrossingBorders #CART #Hopeofpatients #FUCASOApproval #Equecel #MultipleMyeloma #JiahuiHospital #Shanghai #Immunotherapy #MedicalInnovation #MedicalBreakthrough #CancerTreatment #FullyHumanCART

8 months ago

Shanghai Hospital Achieves Complete Remission and Discharge of the 100th Patient with Relapsed/Refractory Lymphoma Treated with CAR-T Therapy

Lymphoma

Ruijin Hospital,

affiliated with Shanghai Jiao Tong University School of Medicine, announced that with continuous exploration in clinical practice, experts have made progress in CAR-T cell therapy for lymphoma, benefiting an increasing number of patients. This advancement is of significant importance for further promoting and expanding the application of CAR-T therapy, allowing more patients to benefit from it.

Lymphoma

is a malignant tumor originating from the lymphatic hematopoietic system and encompasses a family of nearly a hundred different subtypes. Relapse and drug resistance pose major challenges for patients. CAR-T products have the potential to improve treatment outcomes and facilitate the broader application of CAR-T therapy among a wider range of patients in China.

CAR-T therapy

involves genetically modifying T cells to equip them with the ability to recognize tumors, enabling them to kill cancer cells in the body. If natural T cells can be likened to “ordinary soldiers,” then CAR-T cells can be considered as “special forces.” For cancer patients, the 5-year survival rate is an important milestone and a signal of cancer being cured. Achieving a 5-year survival implies that some cancer patients treated with CAR-T therapy can obtain long-term survival without further anticancer drug treatment, truly achieving the possibility of “cancer being cured.” Aunt Qin, the first patient enrolled in China’s CAR-T registered clinical trial in 2018, has achieved sustained complete remission for over 5 years and is about to enter the 6th year.

100th patient

At Ruijin Hospital, the 100th patient with relapsed/refractory lymphoma treated with CAR-T therapy has achieved complete remission and been discharged. The patient, Ms. Xu (alias), is a 41-year-old woman who now has a healthy complexion. She was initially diagnosed with follicular lymphoma and underwent chemotherapy and targeted therapy. However, the disease relapsed three months later, transforming into high-grade B-cell lymphoma. High-grade B-cell lymphoma is highly malignant with a poor prognosis. Professor Zhao Weili from the Hematology Department at Ruijin Hospital conducted a detailed analysis of Ms. Xu’s condition and developed a treatment plan for her. On November 22, 2023, after receiving CAR-T cell infusion, Ms. Xu showed complete remission of the tumor during the follow-up examinations at one month and three months.

To assess whether the condition is suitable for CAR-T therapy, you can submit pathology reports, treatment history, and discharge summaries to the Medical Department of <Advanced Medicine in China> for preliminary evaluation!

You can send electronic copies or photos of genetic testing reports and diagnostic reports to:

Email: doctor.huang@globecancer.com

or WhatsApp+8613717959070

The Medical Department will contact you as soon as receive the reports.

#CARTtherapy #LymphomaTreatment #CompleteRemission #RuijinHospital #MedicalAdvancements #CancerResearch #CARTProgress #HopeForPatients #SurvivingLymphoma #HealthcareInnovation #PatientStories #CancerCure #CARTSuccess #MedicalBreakthrough #ImprovingOutcomes #LymphomaAwareness #FightAgainstCancer #CARTJourney #MedicalMilestone #LongTermSurvival #BeatingCancer #lymphoma #cancerawareness

8 months ago Myeloma

Cross-Border Medical Innovation: Singaporean Patient Confronts Multiple Myeloma in China – A Decisive Journey with CAR-T Therapy

Multiple Myeloma

Singaporean patient, Teresa has been battling multiple myeloma for nearly three years. Despite undergoing various conventional treatments including multi-drug therapy, radiation, and chemotherapy, her condition relapsed with extramedullary plasmacytomas affecting her brain, liver, and multiple bones. Recently, after an online consultation with Dr. Vicky Lee and her team at Shanghai Jiahui International Hospital, she made a significant decision: to undergo FUCASO CAR-T therapy in China.

China not only possesses global-leading clinical experience in CAR-T therapy but also offers high-quality commercialized CAR-T products at a competitive price in the global market. Currently, there is an ample supply of these CAR-T products available in China, which is crucial for patients racing against time. Furthermore, the convenience of a single infusion has attracted international attention.

At Shanghai Jiahui International Hospital, an experienced team of hematologic oncology specialists will tailor a personalized treatment plan for Teresa, providing comprehensive and refined diagnostic and therapeutic services. As a pioneer in CAR-T therapy, Jiahui Hospital is about to bring new hope to Ms. Teresa.

We will continue to monitor Teresa’s treatment progress and provide updates.

#CART #CARTTherapy #HopeReborn #FUCASOApproval #Equecel #MultipleMyeloma #JiahuiHospital #Shanghai #Immunotherapy #MedicalInnovation #MedicalBreakthrough #CancerTreatment #FullyHumanCART

8 months ago Myeloma

$160,000 per dose! The first approved CAR-T therapy in China, Zevor-cel by CARsgen, announces its initial price for the treatment of multiple myeloma.

🌈 $160,000 per dose! 🌈

⭐The first approved CAR-T therapy in China, Zevor-cel by CARsgen, announces its initial price for the treatment of multiple myeloma.

multiple myeloma

Zevor-cel

🌦On March 5th, the fifth approved CAR-T therapy in China, Zevor-cel injection (Zevor-cel) by CARsgen, was priced at $116,000 for its initial release.

Zevor-cel injection is an autologous CAR-T product targeting BCMA. It is the fifth CAR-T therapy approved and marketed in China, following Axicabtagene Ciloleucel by Fosun Kite, Relmacabtagene Autoleucel by JW Therapeutics, Equecabtagene Autoleucel by IASO Bio, and Inaticabtagene Autoleucel by Juventas.

Cheapest CAR-T therapy

🌺Currently, the cheapest approved CAR-T therapy in the world is Inaticabtagene Autoleucel by Juventas. The price has dropped below one million RMB, at 999,000 RMB (equivalent to less than $140,000).

US CAR-T

🌼In 2017, the US FDA approved two CAR-T products, marking the beginning of the era of immunocellular therapy. CAR-T therapy has always been known for its high prices. Just how expensive is it? The two CAR-T therapies approved for sale in the United States are priced at $475,000 (Kymriah) and $373,000 (Yescarta), and these are just the prices of the drugs themselves. The total cost of the treatment far exceeds these amounts.

Multiple Myeloma

🌻For the treatment of multiple myeloma, there are currently two CAR-T products on the US market: Idecabtagene vicleucel by BMS/bluebird bio and ciltacabtagene autoleucel by Legend Bio. They are priced at $419,000 and $465,000, respectively, with a BCMA target and a complete response (CR) rate of 28% and 78%.

In China

⚡ there are also two CAR-T products on the market: Zevor-cel injection by CARsgen and Equecabtagene Autoleucel injection by IASO Bio. They are priced at $160,000 and $162,000, respectively, with the same BCMA target and CR rates as high as 78.6% and 82.4%.

🌤To assess whether the condition is suitable for CAR-T therapy, you can submit pathology reports, treatment history, and discharge summaries to the Medical Department of <Advanced Medicine in China> for preliminary evaluation!

WhatsApp+8613717959070

doctor.huang@globecancer.com

#CARTtherapy #CancerTreatment #Immunotherapy #MultipleMyeloma #BCMA #Zevorcel #CARsgen #MedicalBreakthrough #HealthcareInnovation #PrecisionMedicine #PersonalizedMedicine #MedicalAdvancements #FightAgainstCancer #GlobalHealthcare #AffordableMedicine

#CancerResearch #PatientCare #MedicalTechnology #InnovativeTherapy #HopeForPatients

Menu

Tags Archives: Hope For Patients